Compare Baxter International Inc (BAX) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Trip.com Group Ltd — how do they compare? Baxter International Inc trades at $22.14 (market cap $11.26B), while Trip.com Group Ltd trades at $43.28 (market cap $26.95B). The key difference: Trip.com Group Ltd is far larger — about 2.4× Baxter International Inc's market cap, and Baxter International Inc pays the higher dividend (0.92%). Which is the better fit depends on your goals.
| BAX | TCOM | |
|---|---|---|
Market Cap | $11.26B | $26.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.22 | $78.96 |
52-Week Low | $15.80 | $39.84 |
Enterprise Value | $18.93B | $19.65B |
Dividend Yield | 0.92% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
TCOM trades at $42.36, down 1.03% on the day, with a bearish technical signal and recent earnings misses. The stock shows strong fundamentals with a P/E of 6.36, net income margin of 48.65%, and robust cash flow from operations of $19.63 billion in 2024. However, Q1 2026 earnings missed estimates, and Q2 revenue guidance of 3%-8% growth disappointed investors, contributing to recent price weakness.
The outlook is mixed; strong profitability and low valuation offer upside toward the $56.72 consensus price target, but near-term headwinds include regulatory scrutiny and muted guidance. Risks involve antitrust investigations and domestic travel dependency, yet institutional sentiment remains positive with 67% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
